BioCentury
ARTICLE | Product Development

Oncolytic duos and Dx

February 29, 2016 8:00 AM UTC

Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells.

At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG, are investigating co-administering the therapies with HDAC inhibitors...